HauserAS, GloriamDE, Brauner-OsborneH, FosterSR. Novel approaches leading towards peptide GPCR de-orphanisation. Br. J. Pharmacol., 2020; 177(5): 961–968.
2.
ReiterE, AhnS, ShuklaAK, LefkowitzRJ. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol.2012; 52: 179–97.
3.
Costa-NetoCM, Parreiras-E-SilvaLT, BouvierM. A Pluridimensional View of Biased Agonism. Mol. Pharmacol., 2016; 90(5): 587–595.
4.
NamkungY, Le GouillC, LukashovaV, KobayashiH, HogueM, KhouryE, SongM, BouvierM, LaporteSA. Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET. Nat. Commun. 2016; 7: 12178.
5.
LuttrellLM, MaudsleyS, Gesty-PalmerD. Translating in vitro ligand bias into in vivo efficacy. Cell. Signal. 2018; 41: 46–55.
6.
CuppME, NayakSK, AdemAS, ThomsenWJ. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J. Pharmacol. Exp. Ther., 2013; 345(3): 404–418.
